Table 5. Pathological response when regimen is selected based on TIMP1 or DSG2 expression on IHC by retrospective analysis.
| Sample No. | NAC regimen actually administrated | Regimen selected based on TIMP1 expression | Pathological response | NAC regimen actually administrated | Regimen selected based on DSG2 expression | Pathological response |
|---|---|---|---|---|---|---|
| 1 | PC | PC | positive | PC | SC | |
| 2 | PC | SC | PC | SC | ||
| 3 | SC | PC | SC | SC | positive | |
| 4 | SC | SC | negative | SC | SC | negative |
| 5 | PC | SC | PC | SC | ||
| 6 | PC | PC | positive | PC | PC | positive |
| 7 | PC | SC | PC | SC | ||
| 8 | SC | PC | SC | PC | ||
| 9 | SC | SC | positive | SC | PC | |
| 10 | PC | SC | PC | SC | ||
| 11 | PC | SC | PC | SC | ||
| 12 | PC | PC | positive | PC | SC | |
| 13 | SC | SC | positive | SC | PC | |
| 14 | PC | SC | PC | PC | positive | |
| 15 | SC | PC | SC | PC | ||
| 16 | SC | PC | SC | PC | ||
| 17 | SC | SC | positive | SC | SC | positive |
| 18 | PC | SC | PC | SC | ||
| 19 | SC | SC | negative | SC | PC | |
| 20 | SC | SC | positive | SC | SC | positive |
| 21 | PC | SC | PC | PC | positive | |
| 22 | SC | PC | SC | SC | positive | |
| 23 | PC | PC | positive | PC | PC | positive |
| 24 | SC | PC | SC | PC | ||
| Pathological response rate when regimen is selected by TIMP1 expression | 80% (8/10) | Pathological response rate when regimen is selected by DSG2 expression | 88.9% (8/9) | |||
Abbreviations; NAC: neoadjuvant chemotherapy, IHC: immunohistochemistry, SC: S-1/cisplatin, PC: paclitaxel/cisplatin.